Technical Manual (Japanese version) is available at http://www.dojindo.co.jp/manual/sb06.pdf

General Information

It has been recognized that hydrogen sulfide (H_2S) has an important role as a physicological active substance for vasodilation, cytoprotection, modulation of insulin secretion. Although H_2S is considered as a gaseous molecule such as NO and CO, about 80% of the total sulfide exists as hydrogen sulfide anion (HS^-) under physiological condition. In addition, H_2S easily converts to various biochemical molecules such as persulfides and polysulfides, which react with sulfhydryl moieties in a living body. Therefore, the precise action mechanism of H_2S has not been cleared.

Sodium sulfide (Na₂S) and sodium hydrogen sulfide (NaHS) have been widely used as a H_2S donor. Only instantaneously release of H_2S from Na₂S and NaHS, however, is available in aqueous solution, and threse reagents give a transient stimulation of H_2S .

GYY4137 is a slow-releasing hydrogen sulfide donor developed by P. K. Moore *et al.*¹⁾. Since GYY4137 is water-soluble and continuously releases H₂S by hydrolysis in a neutral aqueous solution, it is reported that GYY4137 shows distinct cellular effects such as anti-hypertensive, anti-atherosclerotic, and anti-tumor activities ²⁻⁵⁾.

$$H_3CO - \stackrel{S}{\longrightarrow} \stackrel{+}{P} - S^- \stackrel{+}{+} H_2 \stackrel{N}{\longrightarrow} O$$

$$GYY4137$$
 $H_3CO - \stackrel{S}{\longrightarrow} \stackrel{+}{P} - S^- \stackrel{+}{+} H_2 \stackrel{N}{\longrightarrow} O$

$$pH7 buffer$$

$$H_2S$$

Fig. 1 H₂S release of GYY4137 by hydrolysis

Contents

-SulfoBiotics- GYY4137

10 mg x 1

Storage Condition

Store at 0-5 °C

Precaution

This reagent releases a toxic hydrogen sulfide gas in a neutral aqueous solution. Refer to the material safety data sheet before using the reagent.

General Protocol

- 1) Dissolve 3.8 mg of GYY4137 with 0.5 ml of ddH $_2$ O to prepare 20 mmol/l GYY4137 Stock Solution. *Store the stock solution at -20 °C and use within two months. Aliquot the solution for longer storage.
- 2) Dilute the 20 mmol/l GYY4137 Stock Solution to an appropriate concentration depending on your experiment. *H₂S release is initiated by addition of the stock solution to neutral buffers or culture medium.

Experimental Example

- H₂S release profile of GYY4137 in PBS -

- Ten microliter (10 μl) of 20 mmol/l GYY4137 Stock Solution was added to 2 ml of PBS to prepare 100 μmol/l GYY4137 (PBS) solution. Then, the solution was incubated at room temperature with sealing.
- The yielded hydrogen sulfide anion was quantified at each time by methylene blue method.

 $\ensuremath{\text{H}_2\text{S}}$ release from GYY4137 in PBS was slow and sustained.




Fig. 2 H₂S release profile of 100 µmol/l GYY4137 in PBS

Reference

1) L. Li, M. Whiteman, Y. Y. Guan, K. L. Neo, Y. Cheng, S. W. Lee, Y. Zhao, R. Baskar, C-H. Tan, and P. K. Moore, "Characterization of a Novel, Water-Soluble Hydrogen Sulfide-Releasing Molecule (GYY4137): New Insights Into the Biology of Hydrogen Sulfide", Circulation, 2008, 117, 2351.

2) M. Whiteman, L. Li, P. Rose, C-H. Tan, D. B. Parkinson, and P. K. Moore, "The Effect of Hydrogen Sulfide Donors of Lipopolysaccharide-Induced Formation of Inflammatory Mediators in Macrophages", *Antioxid. Redox Signal.*, **2013**, *19*, 1749.

3) Z. W. Lee, J. Zhou, C-S. Chen, Y. Zhao, C-H. Tan, L. Li, P. K. Moore, and L-W. Deng, "The Slow-Releasing Hydrogen Sulfide Donor, GYY4137, Exhibits Novel Anti-Cancer Effects *In Vitro and In Vivo*", *PLos One*, **2011**, *6*, e21077.

4) L. Li, B. Fox, J. Keeble, M. Salto-Tellez, P. G. Winyard, M. E. Wood, P. K. Moore, and M. Whiteman, "The complex effects of the slow-releasing hydrogen sulfide donor GYY4137 in a model of acute joint inflammation and in human cartilage cells", *J. Cell. Mol. Med.*, **2013**, *17*, 365.

5) Z. Liu, Y. Han, L. Li, G. Meng, X. Li, M. Shirhan, M. T. Peh, L. Xie, S. Zhou, X. Wang, Q. Chen, W. Dai, C-H. Tan, S. Pan, P. K. Moore and Y. Ji, "The hydrogen sulfide donor, GYY4137, exhibits anti-atherosclerotic activity in high fat fed apolipoprotein E-/- mice", *Br. J. Pharmacology,* **2013**, *169*, 1795.

If you need more information, please contact Dojindo technical service.

Dojindo Laboratories

2025-5 Tabaru, Mashiki-machi, Kamimashiki-gun, Kumamoto 861-2202, Japan Phone: +81-96-286-1515 Fax: +81-96-286-1525 E-mail: info@dojindo.co.jp Web: www.dojindo.co.jp Dojindo Molecular Technologies,Inc.
Tel: +1-301-987-2667 Web:http://www.dojindo.com/
Dojindo EU GmbH
Tel: +49-89-3540-4805 Web: http://www.dojindo.eu.com/
Dojindo China Co., Ltd
Tel: +86-21-6427-2302 Web:http://www.dojindo.cn/